What We are Reading: A Pioneer in GLP-1 Research Fights for Recognition
Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.
Svetlana Mojsov, Ph.D., is a researcher who, early in her career, was influential part of the team of researchers at Massachusetts General Hospital who discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss. Their work and the paper, where she was lead author, eventually led to the development of the blockbuster drugs Victoza, Ozempic and Mounjaro.
But somewhere along the way, Mojsov’s role had been minimized and she didn’t receive awards and recognition that that her colleagues did and was even left off several patents on the research. Several recent articles are working to correct the record, including one in Science and on Stat.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More
